ロード中...

QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS

Circumscribed low-grade glioma is generally driven by MAP kinase pathway activation, and this discovery motivates use of the non-competitive MEK 1/2 inhibitor trametinib for children and adults with progressive disease. However, rash is a common dose-limiting toxicity with trametinib. Accordingly, w...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Archambault, Bridget, Landi, Daniel, Schroeder, Kristin
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847309/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.854
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!